Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$1.41 - $30.75 $1,041 - $22,724
739 Added 4.17%
18,467 $31,000
Q1 2024

May 15, 2024

BUY
$17.68 - $29.57 $34,334 - $57,424
1,942 Added 12.3%
17,728 $524,000
Q4 2023

Feb 14, 2024

SELL
$9.58 - $24.25 $46,625 - $118,024
-4,867 Reduced 23.57%
15,786 $357,000
Q3 2023

Nov 14, 2023

SELL
$12.9 - $18.88 $28,109 - $41,139
-2,179 Reduced 9.54%
20,653 $280,000
Q2 2023

Aug 14, 2023

SELL
$15.63 - $22.01 $47,374 - $66,712
-3,031 Reduced 11.72%
22,832 $392,000
Q1 2023

May 15, 2023

BUY
$19.17 - $27.7 $101,658 - $146,893
5,303 Added 25.79%
25,863 $522,000
Q4 2022

Feb 14, 2023

SELL
$15.92 - $30.52 $12,481 - $23,927
-784 Reduced 3.67%
20,560 $602,000
Q3 2022

Nov 14, 2022

SELL
$14.77 - $25.79 $163,503 - $285,495
-11,070 Reduced 34.15%
21,344 $354,000
Q2 2022

Aug 15, 2022

BUY
$10.8 - $16.91 $350,071 - $548,120
32,414 New
32,414 $32,000
Q1 2022

May 13, 2022

SELL
$8.25 - $18.33 $306,537 - $681,069
-37,156 Closed
0 $0
Q4 2021

Feb 11, 2022

SELL
$9.14 - $21.54 $99,653 - $234,850
-10,903 Reduced 22.69%
37,156 $438,000
Q3 2021

Nov 12, 2021

BUY
$11.76 - $22.49 $565,173 - $1.08 Million
48,059 New
48,059 $1.01 Million

Others Institutions Holding AVTE

About Aerovate Therapeutics, Inc.


  • Ticker AVTE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 24,448,100
  • Market Cap $61.9M
  • Description
  • Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which ...
More about AVTE
Track This Portfolio

Track Parkwood LLC Portfolio

Follow Parkwood LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Parkwood LLC, based on Form 13F filings with the SEC.

News

Stay updated on Parkwood LLC with notifications on news.